



UNIVERSITÀ POLITECNICA DELLE MARCHE
Repository ISTITUZIONALE

Practice pattern for the use of intravenous iloprost for the treatment of peripheral vasculopathy in systemic sclerosis: A case-control study from the Italian national multicenter "SPRING" (Systemic Sclerosis Progression InvestiGation) Registry

This is the peer reviewed version of the following article:

Original

Practice pattern for the use of intravenous iloprost for the treatment of peripheral vasculopathy in systemic sclerosis: A case-control study from the Italian national multicenter "SPRING" (Systemic Sclerosis Progression InvestiGation) Registry / Riccieri, V., Pellegrino, G., Cipolletta, E., Giuggioli, D., Bajocchi, G., Bellando-Randone, S., Dagna, L., Zanframundo, G., Foti, R., Cacciapaglia, F., Cuomo, G., Ariani, A., Rosato, E., Lepri, G., Girelli, F., Zanatta, E., Laura Bosello, S., Cavazzana, I., Ingegnoli, F., De Santis, M., et al.. - In: JOURNAL OF SCLERODERMA AND RELATED DISORDERS. - ISSN 2397-1983. - 9:1(2024), pp. 38-49.

DOI:10.1177/239719832312098091

This version is available at: 11566/326731 since: 2024-04-03T14:41:04Z

Publisher:

Published

DOI:10.1177/23971983231209809

Terms of use:

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. The use of copyrighted works requires the consent of the rights' holder (author or publisher). Works made available under a Creative Commons license or a Publisher's custom-made license can be used according to the terms and conditions contained therein. See editor's website for further information and terms and conditions.

This item was downloaded from IRIS Università Politecnica delle Marche (<https://iris.univpm.it>). When citing, please refer to the published version.

(Article begins on next page)

**PRACTICE PATTERN FOR THE USE OF INTRAVENOUS ILOPROST
FOR THE TREATMENT OF PERIPHERAL VASCULOPATHY IN
SYSTEMIC SCLEROSIS: A CASE-CONTROL STUDY FROM THE
ITALIAN NATIONAL MULTICENTER “SPRING” (Systemic Sclerosis
Progression InvestiGation) REGISTRY**

Valeria Riccieri^{*1}, Greta Pellegrino^{*1,2}, Edoardo Cipolletta³, Dilia Giuggioli⁴, Gianluigi Bajocchi⁵, Silvia Bellando-Randone⁶, Lorenzo Dagna⁷, Giovanni Zanframundo⁸, Rosario Foti⁹, Fabio Cacciapaglia¹⁰, Giovanna Cuomo¹¹, Alarico Ariani¹², Edoardo Rosato¹³, Gemma Lepri⁶, Francesco Girelli¹⁴, Elisabetta Zanatta¹⁵, Silvia Laura Bosello¹⁶, Iliara Cavazzana¹⁷, Francesca Ingegnoli¹⁸, Maria De Santis¹⁹, Giuseppe Murdaca²⁰, Giuseppina Abignano²¹, Nicoletta Romeo²², Alessandra Della Rossa²³, Maurizio Caminiti²⁴, Annamaria Iuliano²⁵, Giovanni Ciano²⁶, Lorenzo Beretta²⁷, Gianluca Bagnato²⁸, Ennio Lubrano²⁹, Ilenia De Andres³⁰, Alessandro Giollo³¹, Marta Saracco³², Cecilia Agnes³³, Federica Lumetti⁴, Amelia Spinella⁴, Luca Magnani⁵, Corrado Campochiaro⁷, Giacomo De Luca⁷, Veronica Codullo⁸, Elisa Visalli⁹, Claudio Di Vico¹¹, Antonietta Gigante¹³, Francesca Saccon³⁴, Maria Grazia Lazzaroni¹⁷, Franco Franceschini¹⁷, Elena Generali¹⁹, Gianna Mennillo²¹, Simone Barsotti²³, Giuseppa Pagano Mariano²⁴, Francesca Calabrese²⁴, Federica Furini³⁵, Licia Vultaggio³⁵, Simone Parisi³⁶, Clara Lisa Peroni³⁶, Gerolamo Bianchi³⁷, Fabrizio Conti¹, Franco Cozzi³⁴, Salvatore D’Angelo²¹, Andrea Doria¹⁵, Enrico Fusaro³⁶, Marcello Govoni³⁵, Serena Guiducci⁶, Florenzo Iannone¹⁰, Carlo Salvarani⁴, Gian Domenico Sebastiani²⁵, Clodoveo Ferri⁴, Marco Matucci-Cerinic⁶ and Rossella De Angelis³ on behalf of SPRING-SIR (Systemic Sclerosis Progression InvestiGation group of the Italian Society of Rheumatology).

* first co-authors

¹ Department of Internal Medicine, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy, Rome, Italy.

² Rheumatology Department, IRCCS Ospedale Galeazzi- Sant’Ambrogio, Milan, Italy.

³ Rheumatology Unit, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy.

⁴ Rheumatology Unit, School of Medicine, University of Modena and Reggio Emilia, Modena, Italy, Modena, Italy.

⁵ Rheumatology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy, Reggio Emilia, Italy.

⁶ Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence & Division of Rheumatology AOUC, University of Florence, Florence, Italy.

⁷ Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy, Milano, Italy.

⁸ Department of Rheumatology, Policlinico San Matteo, Pavia, Italy.

⁹ Rheumatology Unit, A.O.U Policlinico S. Marco, Catania, Italy, Catania, Italy.

¹⁰ Rheumatology Unit, Department of Precision and Regenerative Medicine-Ionian Area, University of Bari "Aldo Moro", Bari, Italy.

¹¹ Department of Precision Medicine - University of Campania "Luigi Vanvitelli", Naples, Italy, Caserta, Italy.

¹² Department of Medicine, Internal Medicine and Rheumatology, Azienda Ospedaliero Universitaria di Parma, Parma, Italy, Parma, Italy.

¹³ Department of Translational and Precision Medicine, Sapienza University of Rome, Italy, Roma, Italy.

¹⁴ Department of Medicine, Rheumatology Unit, Ospedale GB Morgagni - L Pierantoni, Forlì, Italy, Forlì, Italy.

¹⁵ Rheumatology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.

¹⁶ Institute of Rheumatology and Affine Sciences, Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, Rome, Italy.

- ¹⁷ Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia; Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, Brescia, Italy.
- ¹⁸ Division of Clinical Rheumatology, ASST Pini, Dept. of Clinical Sciences & Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Research Center for Environmental Health, Università degli Studi di Milano, Milan, Italy, Milano, Italy.
- ¹⁹ Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Rozzano, and Humanitas University, Pieve Emanuele, Milan, Italy, Rozzano, Italy.
- ²⁰ Department of Internal Medicine, University of Genoa, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
- ²¹ Rheumatology Institute of Lucania (IREL) and Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy, Potenza, Italy.
- ²² Rheumatology Unit ASO Santa Croce e Carle, Cuneo, Italy.
- ²³ Department of Rheumatology, University of Pisa, Pisa, Italy, Italy.
- ²⁴ Departmental Rheumatology Unit, Grande Ospedale Metropolitano, Reggio Calabria, Italy, Italy.
- ²⁵ Rheumatology Unit, San Camillo - Forlanini Hospital, Rome, Italy, Italy.
- ²⁶ Hospital of Ariano Irpino, Local Health Department, Ariano Irpino, Avellino, Italy.
- ²⁷ Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico di Milano, Milan, Italy.
- ²⁸ Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
- ²⁹ Department of Rheumatology, University of Molise, Campobasso, Italy.
- ³⁰ Rheumatology Unit, Azienda Ospedaliera di Rilievo Nazionale ed Alta Specializzazione "Garibaldi", Catania, Italy.
- ³¹ Rheumatology Section, Department of Medicine, University of Verona, Verona, Italy.
- ³² Ospedale Mauriziano, Torino, Italy.
- ³³ San Lorenzo Hospital, Carmagnola, Turin, Italy.
- ³⁴ Department of Medicine, Villa Salus Hospital, Venice, Italy.
- ³⁵ Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliera-Universitaria S. Anna di Ferrara, Ferrara, Italy.
- ³⁶ Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin, Italy.
- ³⁷ Rheumatology Unit, Department of Musculoskeletal Sciences, Local Health Trust 3, La Colletta Hospital, Genoa, Italy.

Key words

Systemic sclerosis

Therapy

Intravenous Iloprost

Corresponding author:

Valeria Riccieri

valeria.riccieri@uniroma1.it

Associate Professor of Rheumatology

Department of Internal Medicine, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy, Rome, Italy.

0039 06 49974641

0039 06 49974642 (Fax)

ABSTRACT

Background. Intravenous(IV) iloprost(ILO) has been widely used for the treatment of Systemic Sclerosis (SSc) peripheral vasculopathy. No agreement has been found on the regimen and the dosage of IV ILO in different scleroderma subset conditions.

This study aimed to evaluate the modalities of IV ILO administration within a large cohort of SSc patients from the SPRING Registry and to identify any associated clinical-demographic, instrumental or therapeutic data.

Patients and methods. Data of SSc patients treated with IV ILO for at least one year (case group) were retrospectively analyzed, including different timing and duration of IV ILO session, and compared with those of untreated patients (control group).

Results. Out of 1895 analyzed patients, 937(49%) received IV ILO treatment while 958(51%) were assigned to the control group. Among cases, about 70% were treated every four weeks, 24% with an interval of more than four weeks, and only 6% of less than four weeks.

Most patients receiving the treatment every four weeks, or less, underwent infusion cycle for one day only, while if it was scheduled with an interval of more than 4 weeks, a total number of 5 consecutive days of infusions was the preferred regimen. The comparison between the two groups revealed that patients treated with IV ILO had a higher frequency of DUs($p<0.001$), pitting scars($p<0.001$), diffuse cutaneous involvement($p<0.001$), interstitial lung disease($p<0.002$), as well as higher rates of anti-Topoisomerase I, "late" scleroderma pattern at nailfold videocapillaroscopy. These findings were confirmed by multivariate analysis.

Conclusions. Our data provide a picture on the Italian use of IV ILO among SSc patients and showed that it was usually employed in patients with a more aggressive spectrum of the disease. The disparity of IV ILO treatment strategies in the different centers suggests the need of a rational therapeutical approach based on the clinical characteristics of different patients' subsets.

BACKGROUND

Systemic sclerosis (SSc) is a severe autoimmune disease characterized by a prominent vasculopathy with a wide range of clinical features, such as Raynaud's phenomenon (RP) and digital ulcers (DUs).(1)

Intravenous (IV) iloprost (ILO), is a stable synthetic analogue of prostacyclin used for the treatment of RP and ischemic complications in SSc. In the clinical practice, ILO in infusion cycles has obtained efficient and safe results. (2–5)

According to the EULAR recommendation on SSc, IV ILO is employed for severe RP after failure of oral vasoactive drugs and, as first line therapy, for the treatment of DUs.(6) These endorsements are supported by metaanalyses and Randomized Clinical Trials (RCTs) demonstrating that IV ILO reduces the frequency and severity of RP attacks (4,7,8), and may prevent the occurrence and boost the healing of DUs.(9) Moreover, ILO has been registered for the treatment of severe pulmonary arterial hypertension (PAH) associated to SSc,

144 although it has a strength of recommendation “B”, since data are obtained from one RCT
145 including patients with SSc and other connective tissue diseases.(6)
146 A systematic review of the literature on IV ILO in SSc, enriched by a Delphi consensus
147 exercise, confirmed its efficacy, without identifying accurately the most appropriate
148 regimens, as for dosage, duration, and/or frequency. It should be also considered that all the
149 existing published studies have been conducted on limited numbers of patients.(10)
150 Indeed, there is a great variability on its use in daily clinical practice and therapeutic
151 indications differ among countries: overall, the recommended dosage varies between 0.5
152 to 2.0 ng/kg/min for an infusion of 6h/per day, depending on patient’s tolerance (as reported
153 in the technical data sheet).(11) In some countries, IV ILO is available with the approved
154 indication for RP secondary to SSc for 3-5 days and in Italy also for Buerger’s disease.(10,11)
155 Data derived from expert opinion suggested a 1-3-day monthly regimen for RP and DUs
156 healing, and 1 day monthly for DUs prevention. (10) Therefore, the lack of uniformity on
157 the type of regimen, dosage, frequency, and duration, prompts in practice the use of IV ILO
158 mainly based on personal experience and convenience.
159 Thus, the aim of our study was to evaluate how IV ILO therapy is used and administered
160 by rheumatologists within a large national cohort of SSc patients, included in the Italian
161 “SPRING” (Systemic Sclerosis Progression InvestiGation) Registry, to investigate the
162 association between clinical-demographic, instrumental, and therapeutic data, and to
163 understand whether there were features that could drive its specific timing and dosage.
164

165 PATIENTS AND METHODS

166 In this case-control study we retrospectively evaluated clinical-demographical, instrumental
167 and therapeutical data from patients affected by definite SSc, classified according to the 2013
168 European League Against Rheumatism (EULAR)/ American College of Rheumatology
169 (ACR) criteria,(12) enrolled in the SPRING registry.
170 SPRING project is a prospective cohort study, with a consecutive recruitment of SSc-
171 spectrum cases, promoted by the Italian Society for Rheumatology-SIR in 2015, as a strategic
172 no-profit project involving 37 Italian centers (the reference number of the Coordinating
173 Centre is OSS 15.010, AOU Careggi-Firenze). All patients gave their written informed
174 consent to participate. Study data were collected and managed using Research Electronic
175 Data Capture (REDCap), a web-based application to support data collection. As previously
176 described (13), the cohorts were categorized as RP (primary and suspected secondary), Very
177 Early Diagnosis of SSc (VEDOSS)(14) and definite SSc.(12)
178 At baseline and at yearly follow-up visit, demographic, clinical, instrumental and laboratory
179 features of each patient, aged >18, were collected, together with the disease history, lifestyles,
180 and comorbidities. Information included age, sex, age of disease onset, as well as the
181 following clinical variables: skin signs (sclerodactyly, puffy fingers, calcinosis, and

telangiectasia), peripheral vascular signs (digital pitting scars, DUs, gangrene), presence of comorbidities (smoking habit, arterial hypertension, dyslipidaemia, diabetes). Among instrumental features, non-invasive cardiac diagnostic testing was performed by electrocardiogram (ECG) and trans-thoracic echocardiography (including pulmonary arterial pressure-PAPs estimation). Investigations for lung involvement consisted of pulmonary function tests (total lung capacity-TLC, forced vital capacity-FVC), with diffusion capacity for carbon monoxide (DLCO) and high-resolution computed tomography-HRCT (to detect interstitial lung disease-ILD). Nailfold videocapillaroscopic (NVC) data were collected, using the classification proposed by Cutolo et al.(15) Previous and current treatments were also reported, including both vasodilators/vasoactive drugs (calcium-channel blockers-CCB, prostanoids, endothelin receptor antagonists-ERAs, phosphodiesterase-5 inhibitors-PDE5i, angiotensin converting enzyme inhibitors-ACEi, anti-platelets).

For the study, only patients classified as definite SSc were evaluated, while VEDOSS and RP patients were excluded. The sample selection process is illustrated in Figure 1. From the cohort of definite SSc, those treated with IV ILO were selected, evaluating the different timing of ILO infusions and in details the frequency and duration of infusion itself. The second step was to collect and stratify patients based to the type of IV ILO regimens. Additionally, clinical, demographic and instrumental features, as well as therapies, were compared between SSc patients treated with IV ILO (case group) and those without (control group). Besides, we evaluated if there was any difference among patients treated with different frequency of IV ILO infusion, and among their characteristics, such as the presence of DUs and/or pitting scars, SSc-specific autoantibodies (anti-Topoisomerase 1/Topo 1, anti-centromere/ACA, anti-RNA polymerase), organ involvement, severity of RP, NVC patterns or presence of limited (lcSSc)/diffuse (dcSSc)/sine SSc (ssSSc) subsets of the disease.(13,16)

STATISTICAL ANALYSIS

Descriptive analyses were reported as absolute and relative frequencies for categorical variables, mean and SD for continuous ones. Median (IQR) has been provided in place of mean (SD) when significant asymmetry of distributions was present. The chi-square test was used to compare categorical variables, while quantitative variables were compared using the Student's t test or Mann-Whitney U test depending on their distribution, as appropriate. Multivariable logistic regression analysis was also performed to examine the strength of the association between demographic and clinical variables and the use of IV ILO. The regression model was adjusted for the covariates with a $p < 0.05$ in univariate models. Odds ratio (OR) values were reported with their 95% confidence intervals (95%CI). The level of significance was set at < 0.05 . Data were analyzed using Stata v.14.

220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257

RESULTS

The analysis of SPRING database showed that 1895 out of 2378 patients were classified as definite SSc. Of them 937/1895 (49,45%) were treated (cases) and 958/1895 (50,55%) were not treated (control group) with IV ILO.

The case group was analyzed from a geographical perspective by sorting the overall number of SSc patients enrolled in the entire database, based on their Italian macro-area of origin, which included 911 patients from the North, 339 patients from the Center, and 565 from the South. The IV ILO treatment was found to be more frequently used in Central Italy (189/339-55.7%) compared to the Northern (397/911-43,6%) and Southern macro-areas (269/565-47.6%) (p-value=0.006). A subgroup analysis was conducted to assess differences among patients undergoing IV ILO therapy across the Northern, Central and Southern Italy. It revealed that patients receiving IV ILO in Central Italy exhibited a higher prevalence of pitting scars (141/189-74.6% vs Northern: 244/397-61.5% and Southern: 155/269-57.6%; p-value=0.0001), of dcSSc subset of disease (70/189-37%vs Northern: 95/397-23.9% and Southern: 67/269-27.9%; p-value=0.002) and of a *scleroderma late pattern* at NVC (76/189-40.2% vs Northern: 103/397-25.9% and Southern: 71/269-26.4%; p-value=0.0008) than patients from Northern Central and Southern regions. No statistically significant differences were observed in other clinical manifestations, except for ILD at HRCT, that was more frequently encountered among patients in Northern Italy (117/397-29.5% vs Central: 36/189-19% and Southern 67/269-27.9%; p-value=0.0008).

The main clinical and demographic data of all patients at baseline, including laboratory, and instrumental findings, are shown in Table 1.

The comparison between the two groups revealed that the median age of the controls was significantly higher than that of the cases (61±14 vs 57±14 years ±SD; p-value=0.0001). However, the two groups were well-matched in terms of gender and disease duration.

Almost all patients (99%) in both groups had RP. Regarding other clinical signs of peripheral vasculopathy, patients treated with IV ILO showed a higher frequency of DUs (cases vs controls: 275/934-29.4% vs 132/939-14.0%; p<0.001) and pitting scars (cases vs controls: 584/933-62.5% vs 296/934- 31.7%; p<0.001). Baseline NVC showed a normal or non-specific pattern in 31/921 (3.4%) cases and 59/910 (6.5%) controls, while a NVC *scleroderma pattern* was significantly more frequent among cases (824/921- 89.4%) than controls (775/910- 85.1%; p<0.0001). In addition, cases more frequently presented a “late” *scleroderma pattern* than controls (cases vs controls: 272/921- 29.5% vs 162/910- 17.8% p<0.0001).

In all the Italian SPRING centers, IV ILO was administered between 0.5-2.0 ng/Kg/min for six hours, according to manufacturer indication and patient tolerability.

A detailed description of the differently available regimens of IV ILO treatment in SSc patients, including frequency (<, > or = 4 weeks) and number of days of infusion (from 1 to

6 days) for each cycle, is shown in Table 2. Most of the patients (602/861- 69.9 %) were on IV ILO every 4 weeks, 49/861 (5.7 %) with an interval less than four weeks, and 210/861 (24.4%) with an interval of more than four weeks. Most patients (311/602-51.6 %) on treatment every four weeks, underwent IV ILO infusion for only one day. The single-day cycle was also preferred for patients receiving IV ILO for less than 4 weeks (35/49, 71.4%). When IV ILO was scheduled with an interval of more than four weeks, most of the patients received a total number of 5 consecutive days of infusions (125/210, 59.5%).

Patients who received an IV ILO infusion with an interval of less than every 4 weeks had significantly more DUs (27/49-55.1% of cases) than patients treated every 4 weeks (178/602- 29.5 %) or with an interval of more than 4 weeks (63/210-30%) ($p=0.002$). Similarly, patients on IV ILO infusion more often over 4 weeks reported more severe RP than subjects treated with other infusion schedules (IV ILO<4 weeks $N=22/49$ -44.8%, IV ILO every 4 weeks $N=136/602$ -22.5%, IV ILO>4 weeks $N=42/210$ -20%; $p<0.002$).

No difference was found for other clinical features, NVC patterns or other concomitant vascular therapies based on the different IV ILO regimens.

It should be noted that 129 controls were previously treated with IV ILO. The reasons for withdrawal included: toxicity (36%), recovery of symptoms (21%), presence of comorbidities (8%), and inefficacy (7%).

Besides, patients receiving IV ILO therapy showed a more aggressive disease (Table 1): a significantly higher proportion of cases were dcSSc (25.5% vs 13.1%, $p<0.0001$), showed ILD on HRCT (38.2% vs 31.5% $p=0.002$), DUs and pitting scars (62.5% vs 31.7% $p<0.0001$, for both. This observation is also consistent with the serological findings (Table 1), as patients on IV ILO therapy were more frequently anti-Topo (40.3% vs 28.9% p -value <0.0001), while controls were more frequently ACA positive (24.4% vs 36.7%, p -value <0.0001). In contrast, controls showed a higher percentage of patients with ssSSc (18.7% vs 5.9% $p<0.0001$).

A detailed description of previous or ongoing treatments in 937 patients on IV ILO therapy, and in 958 controls is reported in Table 3; as expected ERA (290/937-30.9% vs 110/958-11.5%; p -value <0.0001) and anti-platelet agents (446/937-47.6% vs 385/958-40.2%; p -value 0.001) were prescribed more frequently in cases while there was no significant difference in the use of CCBs-and PDE5-inhibitors between the two groups.

The multivariate analysis revealed that patients' age ($p<0.0001$), presence of pitting scars ($p<0.0001$), and therapy with ERAs ($p<0.0001$) and/or antiplatelet agents ($p=0.049$) were significantly associated with the IV ILO use (Table 4).

An overall overview of the IV ILO regimens as detected from our study is given in Table 5.

DISCUSSION

Our data show that, in Italian centers, IV ILO is employed in patients with a more aggressive spectrum of the disease, namely those patients with clinical features defined by previous

296 studies (17) as risk factors for disease worsening (i.e. DUs, interstitial lung disease, diffuse
297 cutaneous involvement). Thus, it is partly in agreement with the recent EULAR
298 recommendations. (6) Usually, IV ILO is employed for 3-5 days of infusion, but our study
299 found that different treatment regimens were employed in a large SSc Italian national cohort.
300 The clinical-demographic, laboratory, and instrumental features, as well as other vascular
301 therapies were investigated to identify whether there was a preferential regimen, given the
302 absence of well-defined guidelines on the use of IV ILO in SSc.

303 Almost half of all the SSc cases, amounting to 1895, were on IV ILO, and up to date no study
304 on such a large population has been reported in the literature.

305 A different geographical distribution of the IV ILO was recorded among the main Italian
306 macro-areas, as a significant higher percentages of SSc patients treated with IV ILO were
307 resident in Central and Southern Italy, rather than Northern Italy. This finding may result
308 quite paradoxical because Northern regions have a colder average annual climate and
309 therefore patients should be affected with a more severe RP and DUs.(5) Indeed, our
310 analysis showed that patients from Central Italy more frequently have some disease features
311 indicating typical of a more severe form of disease, especially regarding peripheral vascular
312 microangiopathy (pitting scars, scleroderma late pattern) similarly to what was found in a
313 previous clinical-demographical analysis of Spring Registry that have shown as patients
314 from Southern Italy were characterized by a more aggressive disease, accounting for a
315 greater need of IV ILO treatment(18). The different geographical distribution of SSc subsets
316 has been previously emphasized, and may probably be related to referral bias as well to
317 different environmental and/or genetic factors .(18)

318 According to the 2017 EULAR recommendations for the treatment of SSc, IV ILO is
319 indicated for RP management after failure of oral vascular therapies such as CCB and PDE5i
320 or as first choice for DU healing(6). Almost all cases (99%) complained about RP, while only
321 one third presented DUs. However, as this study is a cross sectional analysis, it was not
322 possible to clearly identify the reason for prescribing IV ILO, although we can hypothesize
323 that the presence of RP was the main indication, in agreement with the results of expert
324 consensus.(10) Moreover, the comparison of the clinical characteristics of cases and controls
325 showed that IV ILO is prescribed to those SSc patients presenting a more severe vascular
326 involvement, as cases were more frequently affected by DUs and pitting scars and exhibited
327 a higher incidence of a "late" scleroderma pattern at NVC. Additionally, ERA and anti-platelet
328 treatments were prescribed more frequently in cases than controls. In our SSc cases, it is
329 clear that the manifestations of SSc vasculopathy seem to drive the prescription of IV ILO,
330 in line with EULAR recommendations.(6)

331 In addition, cases treated with IV ILO were more frequently dcSSc, anti-Topo I positive and
332 affected by ILD in respect to controls. This observation highlights that in the real life the
333 prescription of IV ILO is also guided by the whole SSc severity. A similar finding was

334 observed in previous studies .(19,20) In our IV ILO treated patients the higher ILD
335 prevalence is not surprising, as DUs and anti-Topo I are present in more severe patients,
336 including those with ILD (21,22) . It is interesting to note that, despite the lack of RCTs, ILO
337 seemed able to improve skin thickness and pulmonary arterial systolic pressure in
338 observational studies (23,24,25), again suggesting its use in the more aggressive subsets of
339 the disease.

340 The very recent 2023 update of EULAR recommendations for the treatment of SSc still do
341 not specify the dose or the therapeutic regimen for IV ILO.(26) Currently, no trials are
342 available providing guidance on the regimen. In some countries, IV ILO is available and
343 approved for RP secondary to SSc, for 3-5 consecutive days cycle, with no indication on the
344 infusion frequency. Thus, according to patients characteristics(10) and the organization of
345 the hospital center, the physician may consequently choose the best regimen, which
346 includes dosage, duration and frequency.(10) In the future, portable infusion pumps might
347 be applied to selected subjects with a remote monitoring system, managed by expert
348 physician or nurse, thus sparing costs for the patients and the centers.(27)

349 As regards concomitant vascular therapies, a combination strategy with IV ILO is
350 considered the best therapeutic option for RP refractory to oral therapies as well as for
351 DUs.(28) Antiplatelet drugs, used by nearly 50% of our cases, are possibly prescribed with
352 IV ILO in preventing DUs, as recommended in the PROSIT study (28). The combination of
353 ILO+ERAs is believed to be aimed to increase the rate of healing for DUs(18), and prevent
354 the development of new DU(29). In fact, in a long-term follow-up, ILO+ERAs has proven to
355 increase fingertip blood perfusion and the absolute nailfold capillary number/mm, reducing
356 of 80% the incidence of new DU (30).

357 One of the greatest concerns for the use of IV ILO is represented by the choice of its
358 administration regimen.(10) Neither in the EULAR recommendations nor in the
359 manufacturer datasheet a specific dosage, duration or frequency of infusion are indicated,
360 the latter only suggesting that the drug should be administered at a dose of 0.5-2
361 ng/kilogram of body weight (kg)/min. This was also the most frequent dosage employed in
362 our cohort. In a prospective RCT on 46 SSc subjects, an 8-hour IV ILO infusion was used as
363 a daily dose of 2 ng/kg/min for 5 days.(8) Another placebo controlled double-blind study on
364 131 SSc patients, showed IV ILO efficacy in reducing severity, frequency, and duration of
365 RP at a dosage of 2 ng/kg/min over 6 hours a day for 5 consecutive days.(4) In 28 SSc patients,
366 Auriemma et al. showed an amelioration of RP severity and number of RP attacks reduction
367 using a median lower dosage (0.5-2 ng/kilogram of body weight (kg)/min) for 1-3 days every
368 30 days.(31) However, similar results were detected also with different approaches
369 including higher or lower dosages of ILO (32).

370 In most of our patients, the treatment regimen was one-day IV ILO every 4 weeks. This
371 result is in agreement with the report suggesting that IV ILO could be administered 1-3 days
372 monthly to treat RP and DUs healing and one day per month for DU prevention.(10)
373 Thus, in our study the reason for driving the choice of a more frequent infusion may mainly
374 be due to a more severe vascular disease characterized by RP, DUs and pitting scars of the
375 extremities.

376 Attention was also focused on the number of infusions per cycle ranging from a single-day
377 dose or cycles of 2 to 5 consecutive days. A single-day infusion was used for treatment
378 regimens every 4 weeks or less, while when IV ILO was scheduled for infusions with an
379 interval of more than 4 weeks, 5 consecutive days of infusions were the most frequently
380 used regimen.

381 The strength of the current study is represented by the extensive data obtained from a
382 nationwide registry, which provides insights into the real-life IV ILO regimens of tertiary-
383 rheumatology referral centers. At the same time, this type of data collection may have some
384 limitations, including the heterogeneity of the involved centers from different areas of the
385 country with potential geographical referral bias (18).

386 In conclusion, the observed data indicate that the choice of the IV ILO dosage and duration
387 of a single infusion are generally made according to the main recommendations suggested
388 in the datasheet. In particular, the following regimens have been most frequently detected
389 in the Italian centers:

- 390 • dosage range = 0.5-2 ng/kg/min (tapered according to patient's needs);
- 391 • infusion duration = six consecutive hours for each cycle (as reported in the
392 manufacturer datasheet);
- 393 • infusion frequency = more often than 4 weeks in the presence of severe vascular
394 features; every 4 weeks or more in stable RP;
- 395 • cycle frequency = single-day infusion, if repeated within 4 weeks; from 2 to 5
396 consecutive days, for intervals longer than 4 weeks.

397 Overall, the frequency and dosage of IV ILO administration depends on the severity of both
398 peripheral vascular involvement (i.e., RP and DUs) and SSc variants. For a shared
399 therapeutical approach, appropriate RCTs should be planned, allowing to elaborate the
400 most effective and well-tailored IV ILO treatment modalities for different SSc patients'
401 subgroups.

402
403

404

405 **Acknowledgements**

406 This study was supported by the Italian Society for Rheumatology (SIR)

407

408 *Convenors*
409 Clodoveo Ferri, University of Modena & Reggio Emilia, Italy; clodoveo.ferri@unimore.it
410 Marco Matucci-Cerinic, University of Florence, Italy; marco.matuccicerinic@unifi.it
411
412 *Investigators (in alphabetical order)*
413 Abignano Giuseppina, AOR San Carlo di Potenza; g.abignano@hotmail.com
414 Agnes Cecilia, Ospedale San Lorenzo, Carmagnola (TO), ASL-TO5
415 Amato Giorgio, AOU Policlinico – Vittorio Emanuele, Catania; giorgioamato@hotmail.it
416 Ariani Alarico, AOU Parma; dott.alaricoariani@libero.it
417 Bagnato Gianluca, Università degli Studi di Messina; gianbagnato@gmail.com
418 Bajocchi Gianluigi, Arcispedale S. Maria Nuova, Reggio Emilia; gianluigi.bajocchi@asmn.re.it
419 Barsotti Simone, AOU Santa Chiara, Pisa; simone.barsotti@outlook.com
420 Bellando-Randone Silvia, University of Florence; s.bellandorandone@gmail.com
421 Benenati Alessia, AOU ‘Policlinico - Vittorio Emanuele, Catania; alessia.benenati@libero.it
422 Beretta Lorenzo, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano; lorberimm@hotmail.com
423 Bianchi Gerolamo, ASL3 Genova; gerolamo.bianchi@asl3.liguria.it
424 Bosello Silvia, Policlinico “A. Gemelli” –IRCCS – UOC di Reumatologia; Roma; silvia.bosello@libero.it
425 Cacciapaglia Fabio, UO Reumatologia – DETO, Università di Bari; fabio.cacciapaglia79@gmail.com
426 Calabrese Francesca, SSD Reumatologia, Reggio Calabria; francescacalabrese81@virgilio.it;
427 Caminiti Maurizio, Ospedale Bianchi-Melacrino-Morelli, SSD Reumatologia, Reggio Calabria; mauriziocaminiti@tin.it
428 Campochiaro Corrado, Ospedale S. Raffaele, Milano; corradocampochiaro@gmail.com
429 Carignola Renato, AOU San Luigi Gonzaga, Orbassano (TO); renatocarigno@gmail.com
430 Cavazzana Ilaria, Spedali Civili di Brescia; ilariacava@virgilio.it
431 Ciano Giovanni, Ospedale Ariano Irpino, ASL Avellino; giovanni.ciano55@gmail.com;
432 Cipolletta Edoardo, Clinica Reumatologica, Università Politecnica delle Marche, Ancona; edo.cipo@hotmail.it
433 Codullo Veronica, Policlinico San Matteo, Pavia; veronicacodullo@yahoo.it
434 Cozzi Franco, Villa Salus, Mestre; franco.cozzi@unipd.it
435 Cuomo Giovanna, Università degli Studi della Campania - Luigi Vanvitelli, Napoli; giovanna.cuomo@unicampania.it
436 D’Angelo Salvatore, AOR San Carlo di Potenza; saldangelo@katamail.com
437 Dagna Lorenzo, Ospedale S. Raffaele, Milano; dagna.lorenzo@hsr.it
438 Dall’Ara Francesca, UO Medicina Interna-Ambulatorio Reumatologia, Ospedale di Lodi; francesca.dallara@gmail.com
439 De Andres Ilenia, AO ARNAS Garibaldi, Catania; ilenia.deandres@gmail.com
440 De Angelis Rossella, Clinica Reumatologica, Università Politecnica delle Marche, Ancona; r.deangelis@staff.univpm.it
441 De Cata Angelo, Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo (FG); a.decata@operapadrepio.it
442 De Luca Giacomo, Ospedale S. Raffaele, Milano; deluca.giacomo@hsr.it
443 De Santis Maria, Istituto Clinico Humanitas, Rozzano, Milano; maria.desantis@humanitas.it
444 Della Rossa Alessandra, AOU Santa Chiara, Pisa; a.dellarossa69@gmail.com
445 Di Vico Claudio, Università degli Studi della Campania “Luigi Vanvitelli”; claudio.divico@unicampania.it
446 Doria Andrea, Università degli Studi di Padova; adoria@unipd.it
447 Doveri Marica, ASL3 Genova; marica.doveri@asl3.liguria.it
448 Foti Rosario, AOU Policlinico San Marco, Catania; rosfoti5@gmail.com
449 Furini Federica, Department of Medical Sciences, University of Ferrara; fefe.furini@gmail.com
450 Fusaro Enrico, AOU Città della Salute e della Scienza di Torino; fusaro.reumatorino@gmail.com
451 Generali Elena, Istituto Clinico Humanitas, Rozzano, Milano; e.generali@gmail.com
452 Gigante Antonietta, Università degli Studi “La Sapienza”, Roma; antonietta.gigante@uniroma1.it
453 Giollo Alessandro, AOUI Verona; alessandro.giollo@univr.it
454 Girelli Francesco, Ospedale GB Morgagni, Forlì; francesco.girelli@auslromagna.it
455 Giuggioli Dilia, University of Modena/Reggio Emilia; dilia.giuggioli@unimore.it
456 Govoni Marcello, AOU S. Anna, Ferrara; gvl@unife.it
457 Guiducci Serena, University of Florence; s.guiducci@hotmail.com
458 Iannone Florenzo, UO Reumatologia– DETO, Università di Bari; florenzo.iannone@uniba.it
459 Ingegnoli Francesca, Università degli Studi di Milano; francesca.ingegnoli@unimi.it
460 Iuliano Anna Maria, AO San Camillo Forlanini, Roma; annamariaiuliano@hotmail.it
461 Lazzaroni Maria Grazia, Spedali Civili and University of Brescia; mariagrazialazzaroni@gmail.com
462 Lepri Gemma, University of Florence; lepri.gemma@gmail.com
463 Lubrano Ennio, Università del Molise, Campobasso; ennio.lubrano@unimol.it
464 Lumetti Federica, University of Modena & Reggio Emilia; fedelumetti@gmail.com
465 Magnani Luca, Arcispedale S. Maria Nuova, Reggio Emilia; luca.magnani@ausl.re.it
466 Mennillo Gianna, AOR San Carlo di Potenza; giannaangelamennillo@virgilio.it
467 Murdaca Giuseppe, Department of Internal Medicine, University of Genoa, IRCCS Ospedale Policlinico San Martino,
468 Genoa, Italy; giuseppe.murdaca@unige.it
469 Pagano Mariano Giuseppe, Ospedale Bianchi-Melacrino-Morelli, Reggio Calabria; giusypaganomariano@libero.it

470 Parisi Simone, AOU Città della Salute e della Scienza, Torino; simone.parisi@hotmail.it
471 Pellegrino Greta, Sapienza, Università di Roma; greta.pellegrino01@gmail.com
472 Peroni Clara Lisa, AOU Città della Salute e della Scienza, Torino; claralisaperoni@gmail.com
473 Pigatto Erika, UOC Medicina Interna, Ospedale San Bassiano, Bassano del Grappa, Vicenza; erika.pigatto@gmail.com
474 Riccieri Valeria, Sapienza Università di Roma; valeria.riccieri@uniroma1.it
475 Romeo Nicoletta Rheumatology Unit ASO Santa Croce e Carle, Cuneo; romeo.n@ospedale.cuneo.it
476 Rosato Edoardo, Università degli Studi di Roma “La Sapienza” Policlinico Umberto I; edoardo.rosato@uniroma1.it
477 Sambataro Gianluca, Azienda Ospedaliera Cannizzaro, Catania
478 Saracco Marta, Ospedale Mauriziano, Torino; marta.saracco@gmail.com
479 Sebastiani Giandomenico, AO San Camillo Forlanini, Roma; gsebastiani@scamilloforlanini.rm.it
480 Spinella Amelia, University of Modena & Reggio Emilia; amelia.spinella@gmail.com
481 Talotta Rossella, L. Sacco Hospital, Milan; talotta1@virgilio.it
482 Visalli Elisa, AOU Policlinico San Marco, Catania; elivisa21@gmail.com
483 Vultaggio Licia, AOU S. Anna, Ferrara, licia.vultaggio@unife.it
484 Zanatta Elisabetta, Università degli Studi di Padova; elisabetta.zanatta@yahoo.it
485 Zanframundo Giovanni, Policlinico San Matteo, Pavia; gio.zanframundo@gmail.com
486
487

488 **Study Center of the Italian Society of Rheumatology (SIR)**

489 Carlo Scirè, Università degli Studi, Milano-Bicocca, Milan; c.scire@reumatologia.it
490 Greta Carrara, Epidemiology Unit, Italian Society for Rheumatology, Milan, Italy; g.carrara@reumatologia.it
491 Gianpiero Landolfi, Epidemiology Unit, Italian Society for Rheumatology, Milan, Italy; g.landolfi@reumatologia.it
492 Davide Rozza, Epidemiology Unit, Italian Society for Rheumatology, Milan, Italy; d.rozza@reumatologia.it
493 Anna Zanetti, Epidemiology Unit, Italian Society for Rheumatology, Milan, Italy; a.zanetti@reumatologia.it
494
495

496 **Contributors**

497 VR and GP conceived the idea for the study, contributed to the study design, supervised data analysis, interpreted the
498 results, reviewed the literature, co-wrote the first draft of the manuscript and critically reviewed the manuscript. RDA,
499 MMC and CF contributed to the study design, supervised data analysis, interpreted the results and critically reviewed the
500 manuscript. EC performed data analysis, interpreted the results, and critically reviewed the manuscript. DG, GB, SBR,
501 LD, GZ, RF, FC, GC, AA, ER, GL, FG, EZ, SLB, IC, FI, MDS, GM, GA, NR, ADR, MC, AI, GC, LB, GB, EL, IDA,
502 AG, MS, CA, FL, AS, LM, CC, GDL, VC, EV, CDV, AG, FS, MGL, FF, EG, GM, SB, GPM, FC, FF, LV, SP, CLP, GB,
503 FC, FC, SDA, AD, EF, MG, SG, FI, CS, GDS, collected clinical data and critically reviewed the manuscript. All the
504 author approved the submitted manuscript. VR is responsible for the overall content as guarantor and attests that all listed
505 authors meet authorship criteria and that no others meeting the criteria have been omitted.
506

507 **Funding** The authors have not declared a specific grant for this research from any funding agency in the public,
508 commercial or not-for-profit sectors.

509 **Competing interests:** None declared.

510 **Patients consent for publication:** Not applicable

511 **Ethics approval** This study involves human participants and was approved by reference number OSS 15.10 Azienda
512 Ospedaliera Universitaria Careggi-Firenze. Participants gave informed consent to participate in the study before taking
513 part.
514
515
516

517 **ORCID iDs**

518 Valeria Riccieri [http:// orcid. org/ 0000- 0002- 7507- 5483](http://orcid.org/0000-0002-7507-5483)
519 Greta Pellegrino [http:// orcid. org/ 0000- 0002- 1762- 0770](http://orcid.org/0000-0002-1762-0770)
520 Giovanni Zanframundo <http://orcid.org/0000-0001-5042-1282>
521 Fabio Cacciapaglia <http://orcid.org/0000-0001-7479-4462>
522 Alarico Ariani <http://orcid.org/0000-0003-1428-6102>
523 Edoardo Rosato <http://orcid.org/0000-0002-7417-8093>
524 Gemma Lepri <http://orcid.org/0000-0003-4141-6937>
525 Maria De Santis <http://orcid.org/0000-0002-3196-1336>

526 Lorenzo Beretta <http://orcid.org/0000-0002-6529-6258>
527 Ennio Lubrano <http://orcid.org/0000-0003-1471-6467>
528 Giacomo De Luca <http://orcid.org/0000-0002-5306-7714>
529 Veronica Codullo <http://orcid.org/0000-0003-2557-8514>
530 Simone Parisi <http://orcid.org/0000-0003-4496-8315>
531 Anna Zanetti <http://orcid.org/0000-0001-8408-451X>
532 Salvatore D'Angelo <http://orcid.org/0000-0002-7442-1110>
533 Franco Cozzi <http://orcid.org/0000-0003-3627-3927>
534 Fabrizio Conti <http://orcid.org/0000-0002-1897-049X>
535 Andrea Doria <http://orcid.org/0000-0003-0548-4983>
536 Marco Matucci-Cerinic <http://orcid.org/0000-0002-9324-3161>
537 Rossella De Angelis <http://orcid.org/0000-0001-5169-3511>

538

539

540

541

542

543

544

545

546 REFERENCES

547

548 1. Hughes DM, Herrick PAL. Systemic sclerosis. *Br J Hosp Med* 2019;80(9):7.

549 2. McHugh NJ, Csuka M, Watson H, et al. Infusion of iloprost, a prostacyclin analogue, for
550 treatment of Raynaud's phenomenon in systemic sclerosis. *Ann Rheum Dis*
551 1988;47(1):43–7.

552 3. Yardumian DA, Isenberg DA, Rustin M, et al. successful treatment of raynaud's
553 syndrome with iloprost, a chemically stable prostacyclin analogue. *Rheumatol*
554 1988;27(3):220–6.

555 4. Wigley FM. Intravenous Iloprost Infusion in Patients with Raynaud Phenomenon
556 Secondary to Systemic Sclerosis: A Multicenter, Placebo-controlled, Double-Blind Study.
557 *Ann Intern Med* 1994;120(3):199.

558 5. Istituto Superiore per la Protezione e la Ricerca Ambientale. Gli indicatori del clima in Italia nel.

- 559 2019. Anno XV. ISPRA, Stato dell'Ambiente 94/2020 ISBN978-88- 448-0998-0.6.
- 560 6. Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for
561 the treatment of systemic sclerosis. *Ann Rheum Dis* 2017;76(8):1327–39.
- 562 7. Belch JJ, Capell HA, Cooke ED, et al. Oral iloprost as a treatment for Raynaud's
563 syndrome: a double blind multicentre placebo controlled study. *Ann Rheum Dis*
564 1995;54(3):197–200.
- 565 8. Scorza R, Caronni M, Mascagni B, et al. Effects of long-term cyclic iloprost therapy in
566 systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study. *Clin*
567 *Exp Rheumatol* 2001;19(5):503-8.
- 568 9. Pope J, Fenlon D, Thompson A, et al. Iloprost and cisaprost for Raynaud's phenomenon
569 in progressive systemic sclerosis. *Cochrane Database of Systematic Reviews* 1998 [cited on
570 29 novembre 2021]; Available on: <https://doi.wiley.com/10.1002/14651858.CD000953>
- 571 10. Ingegnoli F, Schioppo T, Allanore Y, et al. Practical suggestions on intravenous iloprost
572 in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic
573 literature review and expert consensus. *Semin Arthritis Rheum* 2019;48(4):686–93.
- 574 11. <https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=f>
575 [ooter_001133_042385_RCP.pdf&sys=m0b1l3](https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_001133_042385_RCP.pdf&sys=m0b1l3)
- 576 12. van den Hoogen F, Khanna D, Fransen J, et al. 2013 Classification Criteria for Systemic
577 Sclerosis: An American College of Rheumatology/European League Against
578 Rheumatism Collaborative Initiative: ACR/EULAR Classification Criteria for SSc.

579 *Arthritis & Rheumatism* 2013;65(11):2737–47.

580 13. Ferri C, Giuggioli D, Guiducci S, et al. Systemic sclerosis Progression INvestiGation
581 (SPRING) Italian registry: demographic and clinico-serological features of the
582 scleroderma spectrum. *Clin Exp Rheumatol* 2020;8.

583 14. Avouac J, Fransen J, Walker U, et al. Preliminary criteria for the very early diagnosis of
584 systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials
585 and Research Group. *Ann Rheum Dis* 2011;70(3):476–81.

586 15. Smith V, Herrick AL, Ingegnoli F, et al. Standardisation of nailfold capillaroscopy for the
587 assessment of patients with Raynaud’s phenomenon and systemic sclerosis. *Autoimmun*
588 *Rev* 2020;19(3):102458.

589 16. De Angelis R, Giuggioli D, Bajocchi G, et al. Sex-related Differences in Systemic Sclerosis:
590 A Multicenter Cross-sectional Study From the National Registry of the Italian Society
591 for Rheumatology. *J Rheumatol* 2022;49(2):176–85.

592 17. Becker M, Graf N, Sauter R, et al. Predictors of disease worsening defined by progression
593 of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and
594 Research (EUSTAR) analysis. *Ann Rheum Dis* 2019; 1242-1248.

595


596 18. Ferri C, De Angelis R, Giuggioli D, et al. Geographical heterogeneity of clinical and
597 serological phenotypes of systemic sclerosis observed at tertiary referral centres. The

- 598 experience of the Italian SIR-SPRING registry and review of the world literature.
599 *Autoimmun Rev* 2022;21(10):103159.
- 600 19. Jamart C, Levesque H, Thietart S, et al. Iloprost Duration for Digital Ulcers in Systemic
601 Sclerosis: French Retrospective Study at Two Centers and Literature Review. *Front. Med*
602 2022;9:878970.
- 603 20. Foti R, Amato G, Benenati A, et al. Intravenous iloprost in systemic sclerosis and its effect
604 in cardiopulmonary function: a retrospective observational study. *Eur Rev Med*
605 *Pharmacol Sci* 2022 Nov;26(21):7967-7973.
- 606 21. Morrisroe K, Stevens W, Sahhar J, et al. Digital ulcers in systemic sclerosis: their
607 epidemiology, clinical characteristics, and associated clinical and economic burden.
608 *Arthritis Res Ther* 2019;21(1):299.
- 609 22. De Angelis R, Ferri C, Giuggioli D, et al. Systemic sclerosis sine scleroderma: clinical and
610 serological features and relationship with other cutaneous subsets in a large series of
611 patients from the national registry 'SPRING' of the Italian Society for Rheumatology.
612 *RMD Open* 2023;9(1):e002890.
- 613 23. Airò P, Rossi M, Scarsi M, et al. Disease-modifying effects of long-term cyclic iloprost
614 therapy in systemic sclerosis. A retrospective analysis and comparison with a control
615 group. *Clin Exp Rheumatol* 2007;25(5):722-77
- 616 24. Caravita, S. Long-term effects of intermittent Iloprost infusion on pulmonary arterial
617 pressure in connective tissue disease. *Eur J Intern Med* 2011; 22: 518-521

- 618 25. Foti R, Visalli E, Amato G, et al. Long-term clinical stabilization of scleroderma patients
619 treated with a chronic and intensive IV iloprost regimen. *Rheumatol Int.* febbraio
620 2017;37(2):245–9.
- 621 26. Del Galdo F, Lescoat A, Conaghan PG, et al. OP0234 2023 update of eular
622 recommendations for the treatment of systemic sclerosis. *Ann Rheum Dis* 2023;82(Suppl
623 1):154–5.
- 624 27. Faggioli P, Zaccara E, Castelnovo L, et al. A new digital health tool for the telemonitoring
625 of patients with scleroderma during iloprost administration: a feasibility and
626 acceptability study. *Eur Rev Med Pharmacol Sci* 2023;27(2):799–804.
- 627 28. Negrini S, Magnani O, Matucci-Cerinic M, et al. Iloprost use and medical management
628 of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from
629 the PROSIT study. *Clin Exp Med* 2019;19(3):357–66.
- 630 29. Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers
631 related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind,
632 placebo-controlled trial. *Ann Rheum Dis* 2011;70(1):32–8.
- 633 30. Trombetta AC, Pizzorni C, Ruaro B, et al. Effects of Longterm Treatment with Bosentan
634 and Iloprost on Nailfold Absolute Capillary Number, Fingertip Blood Perfusion, and
635 Clinical Status in Systemic Sclerosis. *J Rheumatol* 2016;43(11):2033–41.
- 636 31. Artlett CM, Smith JB, Jimenez SA. Identification of Fetal DNA and Cells in Skin Lesions
637 from Women with Systemic Sclerosis. *N Engl J Med* 1998;338(17):1186–91.

638 32. Kawald A, Burmester GR, Huscher D, et al. Low versus High-dose Iloprost Therapy
639 Over 21 Days in Patients with Secondary Raynaud’s Phenomenon and Systemic
640 Sclerosis: A Randomized, Open, Single-center Study. *J Rheumatol.* 2008;35(9):1830-7.

641 **Figure 1. The selection process of the sample: from the SPRING Registry to the definition of**
642 **case and control cohorts.**



643 Legend: pts: patients; RP: primary Raynaud’s phenomenon; VEDOSS: Very Early Systemic Sclerosis; SSc: Systemic
644 Sclerosis; IV ILO: intravenous iloprost.
645
646
647
648
649
650
651

Table 1. Comparison of clinical, demographic, and instrumental characteristics between SSc patients treated (cases) and not treated (controls) with IV ILO

Legend: SSc: Systemic Sclerosis; IV ILO: intravenous iloprost; lcSSc: limited cutaneous Systemic Sclerosis; dcSSc: diffuse cutaneous Systemic Sclerosis; ssSSc: sine scleroderma Systemic Sclerosis; ILD: interstitial lung disease; HRTC: High Resolution Computed Tomography; DLCO:diffusing capacity for carbon monoxide; FVC: forced vital capacity; PAH: pulmonary arterial hypertension;
ANA: Antinuclear antibodies; ACA: anticentromere antibodies; ILD: interstitial lung disease; HRTC: High Resolution Computed Tomography
SD: standard deviation
ns: not significant
[§] =missing data
**confirmed by right heart catheterization

Table 2. Different regimens of IV ILO treatment in the cases group: frequency (<, > or = 4 weeks) and number of infusions (from 1 to 6 days) for each cycle

		Frequency of IV ILO cycles			
		<4 weeks	=4 weeks	>4 weeks	Total N (%)
Length of each IV ILO cycle (days)	1	35 (71.4)	311 (51.6)	26 (12.4)	372 (43.2)
	2	1 (2.0)	104 (17.3)	8 (3.8)	113 (13.1)
	3	8 (16.4)	69 (11.5)	9 (4.3)	86 (10.0)
	4	5 (10.2)	27 (4.5)	38 (18.1)	70 (8.2)
	5	0 (0)	87 (14.4)	125 (59.5)	212 (24.6)
	6	0 (0)	4 (0.7)	4 (1.9)	8 (0.9)
	Total N (%)	49 (5.7)	602 (69.9)	210 (24.4)	861 (100)*

Legend: IV ILO: intravenous iloprost

*Total number of patients with available data

692
693
694
695

Table 3. Concomitant vascular therapies carried out by cases and controls.

	SSc pts under IV ILO N= 937	SSc pts not under IV ILO N= 958	p-value
Mean age $\pm$ SD	57 $\pm$ 14	61 $\pm$ 14	0.0001
Mean disease duration (years) $\pm$ SD	14.1 $\pm$ 10.1	13.4 $\pm$ 10.9	ns
Sex (female) <i>n</i> (%)	822 (87.7%)	859 (89.6%)	ns
lcSSc-dcSSc- ssSSc <i>n</i> (%) [§]	624 (68%) - 239 (25.5%)- 55 (5.9%) [19]	631 (68%) -126 (13.1%)- 174(18.7%) [27]	<0.0001
Raynaud’s phenomenon <i>n</i> (%)	931 (99.3%)	948 (98.9%)	ns
Pitting scars <i>n</i> (%) [§]	584 (62.5%) [4]	296 (31.7%) [24]	<0.0001
Digital ulcers <i>n</i> (%) [§]	275 (29.4%) [3]	132 (14.0 %) [19]	<0.0001
Gangrene <i>n</i> (%) [§]	13 (1.4%) [5]	5 (0.5%) [23]	ns
Teleangiectasias <i>n</i> (%) [§]	598 (64.1%) [5]	537 (57.1%) [19]	0.002
Oesophageal involvement <i>n</i> (%) [§]	435 (46.41%) [139]	437 (45.61%) [164]	ns
Renal crisis <i>n</i> (%) [§]	13 (1.4%) [25]	9 (0.9%) [48]	ns
Cardio-pulmonary involvement			
Symptoms <i>n</i> (%) [§]	359 (38.3%) [93]	357 (37.2%) [115]	ns
ILD at HRCT <i>n</i> (%)	358 (38.2%)	302 (31.5%)	ns
Mean DLCO (%) $\pm$ SD	66.45 $\pm$ 18.4 [262]	70.9 $\pm$ 20.3 [299]	<0.0001
Mean FVC (%) $\pm$ SD	99.8 $\pm$ 22 [228]	102.6 $\pm$ 22 [264]	0.001
PAH** <i>n</i> (%)	12 (1.3%)	19 (2.0%)	ns
Traditional risk factors			
Smokers <i>n</i> -(%)	96 (10.2%)	106 (11.0%)	ns ns ns
Arterial hypertension <i>n</i> (%)	204 (21.8%)	248 (25.9%)	ns
Dyslipidemia <i>n</i> (%)	95 (10.1%)	114 (11.9%)	ns
Diabetes <i>n</i> (%)	22 (2.3%)	34 (3.5%)	ns ns
Serological [§]	[4]	[38]	
ANA positive <i>n</i> (%)	916 (98.2%)	890 (96.7%)	0.049
Anti-Topoisomerase1 antibody positive <i>n</i> (%)	376 (40.3%)	266 (28.9%)	<0.0001
ACA positive <i>n</i> (%)	228 (24.4%)	338 (36.7%)	<0.0001
Anti-RNA polymerase 3 antibody positive <i>n</i> (%)	13 (1.4%)	15 (1.6%)	ns
NVC patterns [§]	[16]	[48]	
Normal/non specific <i>n</i> (%)	31 (3.4%)	59 (6.5%)	<0.0001

Scleroderma pattern <i>n</i> (%)	824 (89.4%)	775 (85.1%)	<0.0001
Early <i>n</i> (%)	142 (15.4%)	223 (24.5%)	
			<0.0001
Active <i>n</i> (%)	410 (44.5%)	390 (42.8%)	<0.0001
Late <i>n</i> (%)	272 (29.5%)	162 (17.8%)	

696

Treatment	SSc pts under IV ILO N= 937	SSc pts not under IV ILO N= 958	p-value
Calcium-channel blockers			
- ongoing <i>n</i> (%)	498 (53.1%)	478 (49.9%)	Ns
- past or never done therapy <i>n</i> (%)	439 (47.0%)	480 (50.1%)	
PDE5 inhibitors			
- ongoing <i>n</i> (%)	34 (3.6%)	36 (3.8%)	ns
- past or never done therapy <i>n</i> (%)	903 (96.5%)	922 (96.2%)	
Endothelin receptor antagonists			
- ongoing <i>n</i> (%)	289 (30.9%)	108 (11.3%)	<0.0001
- past or never done therapy <i>n</i> (%)	648 (69.2%)	850 (88.7%)	
Anti-platelet agents			
- ongoing <i>n</i> (%)	446 (47.6%)	381 (39.7%)	0.001
- past or never done therapy <i>n</i> (%)	491 (52.5%)	577 (60.2%)	

Legend: SSc: Systemic Sclerosis; IV ILO: intravenous iloprost; ns: not significant; PDE5: phosphodiesterase type 5.

697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718

719
720
721
722

Table 4. Univariate and multivariate analysis for variables associated with IV ILO treatment.

	Univariate analysis OR (95%CI)	p-value	Multivariate analysis OR (95%CI)	p-value
Age	0.98 (0.97-0.99)	<0.0001	0.98 (0.97-0.99)	<0.0001
dcSSc	1.92 (1.50-2.44)	<0.0001	1.14 (0.85-1.53)	0.377
Digital ulcers	2.55 (2.02-3.21)	<0.0001	1.16 (0.87-1.55)	0.320
Pitting scars	3.60 (2.98-4.37)	<0.0001	2.70 (2.12-3.44)	<0.0001
Teleangiectasias	1.33 (1.11-1.61)	0.002	0.98 (0.78- 1.22)	0.837
Anti-Topo1 positive	2.08 (1.65-2.62)	<0.0001	1.25 (0.93-1.69)	0.133
Scleroderma pattern at NVC	2.02 (1.30-3.16)	0.002	1.50 (0.91-2.47)	0.109
ILD at HRCT	1.35 (1.12-1.64)	0.002	1.02 (0.81-1.29)	0.878
Ongoing therapy with ERAs	3.47 (2.73-4.43)	<0.0001	1.82 (1.37-2.42)	<0.0001
Ongoing therapy with anti-platelet agents	1.37 (1.14-1.64)	0.001	1.24 (1.00-1.53)	0.049

Legend: OR: Odd Ratio; CI: confidential interval; dcSSc: diffuse cutaneous systemic sclerosis; NVC: nailfold videocapillaroscopy; ILD: interstitial lung disease; HRCT: High Resolution Computed Tomography. ERAs: endothelin receptor antagonists

723
724
725
726
727
728
729
730
731

Table 5. Most frequent IV ILO regimens as detected from our study.

Regimen Information	Value
Dosage range	0.5-2 ng/kg/min (tapered according to patient's need)
Infusion Duration	Six consecutive hours for each cycle (as reported in the manufacturer data sheet)
Infusion Frequency	More frequently than 4 weeks in the presence of severe vascular features; every 4 weeks or more in stable RP
N° sessions/Cycle	Single-day infusion, if IV ILO was repeated every 4 weeks or more often; between 2 and 5 consecutive days/each cycle for cycles interval longer than 4 weeks

Legend:IV ILO: intravenous iloprost; RP: Raynaud's phenomenon

732
733
734